Evaluating the Impact of Different Methods of HPV DNA Testing for Cervical Cancer Screening in Primary Care Settings

Launched by NATIONAL HEALTHCARE GROUP POLYCLINICS · Jul 25, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how different methods of testing for the Human Papillomavirus (HPV) can help detect cervical cancer more effectively in primary care settings. Specifically, it aims to see if allowing women to collect their own samples (self-sampling) for HPV testing, in addition to the usual samples collected by healthcare providers, will lead to more women getting screened and, as a result, increase the detection of high-risk HPV by at least 7.7%.

Women who might be eligible to participate in this trial are Singaporean citizens aged 30 to 69 who are due for cervical cancer screening and have engaged in sexual intercourse. Participants will be asked to provide informed consent and should be able to read and communicate in English, Chinese, or Malay. It's important to note that women who are virgins, pregnant, or have a history of cervical cancer, certain cervical lesions, or have had a total hysterectomy cannot participate. If you join, you can expect to help improve cervical cancer screening methods, which may benefit many women in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 30-69 years old female Singapore citizens
• • Due for cervical cancer screening
• • Engaged in sexual intercourse before
• • Able to give informed consent
• • Able to read and communicate in English, Chinese or Malay
• Exclusion Criteria:
• • Virgo intacta
• • Pregnancy
• • History of cervical cancer, precancerous cervical lesions and total hysterectomy